Ensuring a Comprehensive Diagnosis of CIDP and the Role of EMG

Panelist explain that CIDP remains one of the most diagnostically challenging immune-mediated neuropathies because its symptoms overlap with more common conditions. They outline how evaluating the tempo of progression, proximal and distal weakness, and sensory deficits provides the first diagnostic clues. Electromyography and nerve conduction testing confirm demyelination, whereas cerebrospinal fluid analysis and adherence to consensus criteria help clinicians reach diagnostic certainty.

The conversation highlights how updated electrophysiologic standards, such as slowed conduction velocity and prolonged response latencies, refine diagnostic precision and enable earlier intervention. Integrating laboratory and imaging findings with clinical observation remains critical to distinguishing CIDP from metabolic or hereditary neuropathies.

Panelist conclude that accurate diagnosis requires balancing guideline-driven science with individualized clinical judgment. Establishing this foundation not only directs appropriate therapy but also positions clinicians to monitor long-term response and reduce patient burden through timely, targeted care.